By Stephen Nakrosis
Shares of biopharmaceutical company Cytokinetics were trading in the red in the after-hours market following news the Food and Drug Administration extended the prescription drug user fee act action date for the new drug application for aficamten.
The company is evaluating aficamten to treat patients with obstructive hypertrophic cardiomyopathy, a thickening of the heart muscle.
The FDA said it needed additional time to conduct a full review of the company's proposed risk evaluation and mitigation strategy, Cytokinetics said. No additional clinical data or studies have been requested by the FDA, the company also said.
After the bell, the company's shares were trading 13% lower, at $37.10. The stock closed Thursday's regular session at $42.92, basically flat on the day.
Year to date, the stock is down by over 33%.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 01, 2025 18:45 ET (22:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.